文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

急性神经损伤患者的低钠血症治疗

Treatment of Hyponatremia in Patients with Acute Neurological Injury.
PubMed 文献 · Neurocrit Care · 2017-01-01
一句话结论急性神经损伤患者中,34%接受了调钠治疗,中位触发钠为133 mEq/L,高渗盐水最常用,60%在24小时内血钠升高≥4 mEq/L,但治疗与未治疗患者预后无显著差异。

这项回顾性、多中心、观察性研究纳入17个中心400例ICU患者,包括蛛网膜下腔出血、创伤性脑损伤、脑实质出血或颅内肿瘤,入住ICU至少48小时。34%(137/400)的患者启动了调钠治疗,其中23%在开始治疗时血钠已>135 mEq/L;最常见指征为血钠下降(59%)和脑水肿伴意识改变(18%)。中位治疗触发钠为133 mEq/L(IQR 129-139),各诊断间无差异;低钠血症的发生和治疗在蛛网膜下腔出血(46%)和创伤性脑损伤(40%)中更常见。最常用初始治疗为高渗盐水(62%),其次为口服氯化钠片(31%)和限水(11%);治疗患者中60%在24小时有反应。治疗组与未治疗组预后无统计学显著差异。

要点

  • 急性神经损伤患者中34%(137/400)接受了调钠治疗,中位触发钠为133 mEq/L(IQR 129-139),各诊断间无差异。
  • 低钠血症发生和治疗在蛛网膜下腔出血(49/106,46%)和创伤性脑损伤(39/97,40%)中更常见,脑实质出血26%、肿瘤23%(p=0.001)。
  • 最常用初始治疗为高渗盐水(85/137,62%),其次为口服氯化钠片(42/137,31%)和限水(15/137,11%)。
  • 治疗患者中60%在24小时有反应(血钠升高≥4 mEq/L);治疗组与未治疗组预后无统计学显著差异。
  • 23%(32/137)在开始调钠治疗时血钠已>135 mEq/L;最常见治疗指征为血钠下降(59%)和脑水肿伴意识改变(18%)。

适用人群与场景

  • ICU患者,因蛛网膜下腔出血、创伤性脑损伤、脑实质出血或颅内肿瘤入住ICU至少48小时,来自17个中心,2011年1月1日至2012年7月31日。

诊断标准与关键阈值

  • 调钠治疗触发定义为治疗前血钠值;治疗反应定义为24小时血钠升高≥4 mEq/L。
  • 中位治疗触发钠为133 mEq/L(IQR 129-139),各诊断间无差异。

处置流程与药物剂量

  • 最常见初始治疗为高渗盐水输注(85/137,62%),其次为口服氯化钠片(42/137,31%)和限水(15/137,11%)。
  • 调钠治疗在34%(137/400)的患者中启动,最常见指征为血钠下降(68/116,59%)和脑水肿伴意识改变(21/116,18%)。

研究设计与关键结果

  • 回顾性、多中心、观察性研究,纳入17个中心400例ICU患者,比较调钠治疗组与未治疗组;治疗组入院GCS较低(12 vs 14,p=0.02)、APACHE II评分较高(12 vs 10,p=0.001),两组预后无统计学显著差异。
  • 治疗患者中60%在24小时有反应(血钠升高≥4 mEq/L)。
  • 低钠血症发生和治疗在蛛网膜下腔出血(49/106,46%)和创伤性脑损伤(39/97,40%)中更常见,脑实质出血(27/102,26%)和肿瘤(22/95,23%)较低(p=0.001)。

证据类型、等级与局限

  • 证据类型:回顾性、多中心、观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在急性神经损伤患者中,调钠治疗较常见,中位触发钠为133 mEq/L,高渗盐水为最常用初始治疗,多数治疗患者在24小时有反应。
  • 作者认为需要进一步研究评估各种治疗对患者预后的影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Little data exist regarding the practice of sodium management in acute neurologically injured patients. This study describes the practice variations, thresholds for treatment, and effectiveness of treatment in this population.

METHODS: This retrospective, multicenter, observational study identified 400 ICU patients, from 17 centers, admitted for ≥48 h with subarachnoid hemorrhage (SAH), traumatic brain injury (TBI), intraparenchymal hemorrhage, or intracranial tumors between January 1, 2011 and July 31, 2012. Data collection included demographics, APACHE II, Glascow Coma Score (GCS), serum sodium (Na+), fluid rate and tonicity, use of sodium-altering therapies, intensive care unit (ICU) and hospital length of stay, and modified Rankin score upon discharge. Data were collected for the first 21 days of ICU admission or ICU discharge, whichever came first. Sodium trigger for treatment defined as the Na+ value prior to treatment with response defined as an increase of ≥4 mEq/L at 24 h.

RESULTS: Sodium-altering therapy was initiated in 34 % (137/400) of patients with 23 % (32/137) having Na+ >135 mEq/L at time of treatment initiation. The most common indications for treatment were declining serum Na+ (68/116, 59 %) and cerebral edema with mental status changes (21/116, 18 %). Median Na+ treatment trigger was 133 mEq/L (IQR 129-139) with no difference between diagnoses. Incidence and treatment of hyponatremia was more common in SAH and TBI [SAH (49/106, 46 %), TBI (39/97, 40 %), ICH (27/102, 26 %), tumor (22/95, 23 %); p = 0.001]. The most common initial treatment was hypertonic saline (85/137, 62 %), followed by oral sodium chloride tablets (42/137, 31 %) and fluid restriction (15/137, 11 %). Among treated patients, 60 % had a response at 24 h. Treated patients had lower admission GCS (12 vs. 14, p = 0.02) and higher APACHE II scores (12 vs. 10, p = 0.001). There was no statistically significant difference in outcome when comparing treated and untreated patients.

CONCLUSION: Sodium-altering therapy is commonly employed among neurologically injured patients. Hypertonic saline infusions were used first line in more than half of treated patients with the majority having a positive response at 24 h. Further studies are needed to evaluate the impact of various treatments on patient outcomes.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Human T, Cook AM, Anger B, et al. Treatment of Hyponatremia in Patients with Acute Neurological Injury. Neurocrit Care. 2017. PMID: 28054290. doi:10.1007/s12028-016-0343-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。